Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function

• US 20050214938A1
• Filed: 03/21/2005
• Published: 09/29/2005
• Est. Priority Date: 03/26/2004
• Status: Abandoned Application

• Current Assignee: Asterias Biotherapeutics Incorporated (Lineage Cell Therapeutics, Inc.)
• Original Assignee: Asterias Biotherapeutics Incorporated (Lineage Cell Therapeutics, Inc.)
• Inventors: Gold, Joseph D., Xu, Chunhui
• Application Number:
  US11/085,899
• Publication Number:
  US 20050214938A1
• Time in Patent Office: Days
• US Class Current: 435/366
• CPC Class Codes: C12N 2500/33 other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
• CPC Class Codes: C12N 2501/33 Insulin together with transferrin C12N2500/25; Insulin-like growth factors C12N2501/105
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2533/50 Proteins
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells

Abstract

This disclosure describes clusters of cardiomyocyte lineage cells referred to as cardiac bodies. They can be obtained by differentiating human embryonic stem cells into cells that express cardiomyocyte markers, and separating cells according to their density. Single suspended cells are removed, leaving self-aggregating clusters that can be propagated and enriched in further separation steps. The resulting cardiac bodies express cardiomyocyte markers at levels ˜100-fold above the starting cell population, and undergo spontaneous periodic contraction. The clusters can be used intact or dispersed into single-cell suspensions for use in research, drug screening or the preparation of pharmaceutical compositions for the treatment of cardiac disease.

Claims

1. A composition of cardiac bodies,

wherein a cardiac body is defined as a cluster of cells that undergoes spontaneous contraction, and contains a majority of cells that express cardiac troponin I (cTnI), cardiac troponin T (cTnT), or atrial natriuretic factor (ANF), or α

-cardiac myosin heavy chain (MHC) from an endogenous gene; and

wherein the composition is obtainable by a process comprising;

a) differentiating cells from a pPS cell line obtained from a human blastocyst into a cell population in which at least 20% of the cells express cTnI, cTnT, ANF, or MHC from an endogenous gene,

b) separating cells that are present in the population as single cells from cells that are present as clusters;

c) resuspending the cells present as clusters in nutrient medium;

d) reculturing the resuspended cells in the nutrient medium; and

e) collecting and washing the recultured cells;

thereby obtaining a composition of cardiac bodies that undergo spontaneous contraction, and contain a majority of cells that express cTnI, cTnT, ANF, or MHC from an endogenous gene.

2. The composition of claim 1, wherein the process comprises separating, resuspending, and reculturing the cells three or more times.

3. The composition of claim 1, wherein the population of cells expressing cTnI, cTnT, ANF, or MHC has been produced by:

a) initiating differentiation of the pPS cells in suspension culture by forming embryoid bodies;

b) culturing the initiated cells so that they differentiate into areas that undergo spontaneous contraction;

c) harvesting the differentiated cells;

d) separating the harvested cells into fractions according to their density; and

e) collecting the cell fractions that express cTnI, cTnT, ANF, or MHC from an endogenous gene.

4. The composition of claim 1, wherein the pPS cells are human embryonic stem cells.

5. The composition of claim 1, formulated in an excipient such that administration of the composition to a mammalian subject permits survival and engraftment of cells from the cardiac bodies in the subject.

6. A method of generating the cell composition of claim 1, comprising:

a) differentiating cells from a pPS cell line obtained from a human blastocyst into a cell population in which at least 20% of the cells express cTnI, cTnT, ANF, or MHC from an endogenous gene,

b) separating cells that are present in the differentiated population as single cells from cells that are present as clusters;

c) resuspending the cells present as clusters in nutrient medium;

d) reculturing the resuspended cells in the nutrient medium; and

e) collecting and washing the recultured cells;

thereby generating cell clusters in which at least 50% of the clusters undergo spontaneous contraction.

7. The method of claim 5, wherein the single cells are separated from the clustered cells by allowing the clustered cells to settle from suspension, and cells remaining in suspension are removed.

8. The method of claim 5, wherein the nutrient medium in which the resuspended cells are cultured contains about 20% serum or serum substitute.

9. The method of claim 5, comprising separating, resuspending, and reculturing the cells three or more times.

10. The method of claim 5, wherein the population of cells expressing cTnI, cTnT, ANF, or MHC has been produced by:

a) initiating differentiation of the pPS cells in suspension culture by forming embryoid bodies;

b) culturing the initiated cells so that they differentiate into areas that undergo spontaneous contraction;

c) harvesting the differentiated cells;

d) separating the harvested cells into fractions according to their density; and

e) collecting the cell fractions that express cTnI, cTnT, ANF, or MHC from an endogenous gene.

11. The method of claim 10, wherein the embryoid bodies are plated onto a surface coated with gelatin or Matrigel®

.

12. The method of claim 10, wherein the cells are differentiated in a growth environment containing about 20% serum or serum substitute.

13. The method of claim 10, wherein the separating comprises distributing cells in the population according to their density, and collecting cells at a density between ˜

1.05 and ˜

1.075 g/mL.

14. The method of claim 5, further comprising dispersing the cardiac bodies into a suspension of single cells and/or smaller cell clusters.

15. A population of cardiomyocyte lineage cells, obtained by dispersing the cardiac bodies of claim 1 into a suspension of single cells and/or smaller cell clusters.

16. The method of claim 1, wherein the pPS cells are human embryonic stem cells.